US › Healthcare

Gossamer Bio Inc (GOSS)

US · Healthcare · Biotechnology

$0.18+4.55%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$17.0M
Revenue YoY
+71.5%
Net profit
$-46.7M
Profit YoY
-27.4%
EPS
$-0.20
EPS estimate
$-0.17
Net margin
-275.2%

EPS came in at -0.20 against a street estimate of -0.17 — a miss of 17.6%.

Key statistics

Market cap
$82.9M
Forward P/E
0.0
P/B
2.66
Book value
$-0.69
EPS (TTM)
$-0.79
52-week high
$3.87
52-week low
$0.11
50-day MA
$0.18
200-day MA
$1.39
Beta
2.04

Analyst view

Analysts rate Gossamer Bio Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $3.86.

Shareholding

Insiders
1.52%
Institutions
73.56%

Largest institutional holders

FundStake
Kalehua Capital Management LLC3.62%
BlackRock Inc3.44%
AQR Capital Management LLC2.07%
Vanguard Capital Management, LLC1.92%
ARCH VENTURE CORP1.65%
Octagon Capital Advisors LP1.59%
Samsara BioCapital, LLC1.48%
Balyasny Asset Management LLC1.21%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Gossamer Bio Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.